10 / 13
Advanced Stem Cell 2018
Journal of Stem Cell Biology and Transplantation
ISSN: 2575-7725
Page 45
December 03-04, 2018
Valencia, Spain
15
th
Edition of EuroSciCon Conference on
Advanced Stem Cell &
Regenerative Medicine
D
ental pulpMethylprednisolone (MP), a glucocorticoid steroid,
has an anti-inflammatory action and seems to inhibit the
formationof oxygen free radicalsproducedduring lipidperoxidation
in a spinal cord injury (SCI). Currently MP is the standard therapy
after acute SCI on reported neurological improvements. The
combination therapeutic effect of human umbilical cord blood-
derived mesenchymal stem cells (hUCB-MSCs) for transplantation
time (1d, 7d, and30d) afterMPtreatment on theaxonal regeneration
and on the behavioral improvement in SCI were studied in the rat.
The spinal cord was injured by contusion using a weight-drop at
the level of T9 and MP (30 mg/kg, i.m., 10 min and 4 h) was acutely
administered after injury. hUCB-MSCs were labeled with GFP and
our study performed the efficacy for transplantation time (1d, 7d,
and 30 d) of hUCB-MSCs into the boundary zone of injured site.
Efficacy was determined by histology, anterograde and retrograde
tracing, and behavioral test. We found that hUCB-MSCs with MP
treatment exerted a significant beneficial effect by neuroprotection
and reducing cavity volume. Also the transplantation of hUCB-
MSCs with MP treatment significantly improved functional
recovery. Combined transplantation at 7d after SCI provided
significantly greater efficiency than combined transplantation at 1d
and 30d. These results suggest that transplantation time window
of the hUCB-MSCs with MP treatment give rise to an earlier neuron
protection strategy and effect of cell grafting in SCI. Thus our study
may be considered as a therapeutic modality for SCI.
mlsckb1004@gmail.comTherapeutic effects of human mesenchymal
stem cells with methylprednisolone treatment in
rat spinal cord injury
Lee So Maeng
1
, Sang In Park
2
, Ho Yong Jung
2
and
Yong An Chung
2
1
St. Mary’s Hospital – CUK, Republic of South Korea
2
Clinical Research Insitute (CRI), Incheon St. Mary’s Hospital (CUK), Republic of South Korea
J Stem Cell Biol Transplant 2018, Volume 2
DOI: 10.21767/2575-7725-C1-003